Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuting Sun

Showing results (281-290 of 299) with videos related to

Pageof 30
Sort By:
The Lancet Regional Health. Western Pacific|June 9, 2025
Genetic factors driving the <i>Mycoplasma pneumoniae</i> outbreak among children post-COVID-19 in China: a whole genome analysisWeiwei Jiao, Jie Wang, Cuidan Li, et al.
Cancer Research|February 18, 2017
The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene TranscriptionMatthew Wong, Andrew E L Tee, Giorgio Milazzo, et al.
Cancer Discovery|December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance MutationsAlexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Nature Medicine|June 13, 2018
Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancerYonathan Lissanu Deribe, Yuting Sun, Christopher Terranova, et al.
Cancer Research|October 17, 2015
WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in NeuroblastomaYuting Sun, Jessica L Bell, Daniel Carter, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Science Translational Medicine|May 10, 2019
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphomaLiang Zhang, Yixin Yao, Shaojun Zhang, et al.
Oncotarget|October 21, 2016
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugsPei Y Liu, Nicholas Sokolowski, Su T Guo, et al.
Nature Medicine|August 15, 2018
Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancerYonathan Lissanu Deribe, Yuting Sun, Christopher Terranova, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Pageof 30

Showing results (281-290 of 299) with videos related to

Sort By:
Pageof 30
The Lancet Regional Health. Western Pacific|June 9, 2025
Genetic factors driving the <i>Mycoplasma pneumoniae</i> outbreak among children post-COVID-19 in China: a whole genome analysisWeiwei Jiao, Jie Wang, Cuidan Li, et al.
Cancer Research|February 18, 2017
The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene TranscriptionMatthew Wong, Andrew E L Tee, Giorgio Milazzo, et al.
Cancer Discovery|December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance MutationsAlexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Nature Medicine|June 13, 2018
Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancerYonathan Lissanu Deribe, Yuting Sun, Christopher Terranova, et al.
Cancer Research|October 17, 2015
WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in NeuroblastomaYuting Sun, Jessica L Bell, Daniel Carter, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Science Translational Medicine|May 10, 2019
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphomaLiang Zhang, Yixin Yao, Shaojun Zhang, et al.
Oncotarget|October 21, 2016
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugsPei Y Liu, Nicholas Sokolowski, Su T Guo, et al.
Nature Medicine|August 15, 2018
Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancerYonathan Lissanu Deribe, Yuting Sun, Christopher Terranova, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Pageof 30